Grifols Signs a License and Commercialization Agreement with Rigel Pharmaceuticals for Fostamatinib
Shots:
- Rigel to receive $30M upfront- $297.5M milestones including $20M on EMA approval of fostamatinib and royalties up to 30% on net sales. Grifols to get exclusive rights for fostamatinib in all indications including chronic ITP- autoimmune hemolytic anemia (AIHA)- and IgA nephropathy (IgAN)- in EU and Turkey
- Rigel will retain all global rights for fostamatinib (Ex- EU & Turkey) and will pay $25M to regain rights for fostamatinib in EU and other territories to Grifols. Grifols will have an option to terminate the agreement in six-months
- Fostamatinib is a novel SYK inhibitor approved for thrombocytopenia & chronic immune thrombocytopenia in adult- marketed as Tavalisse (fostamatinib disodium hexahydrate) in the US and has received EMA’s approval for chronic ITP on 4 Oct- 2018
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
